Mitchell J. Schwaber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitchell J. Schwaber has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Yehuda Carmeli
National Center for Infection Control, Israel Ministry of Health, Tel-Aviv
9 shared publications- Shiri Navon-Venezia
The Department of Molecular Biology, The Faculty of Natural Sciences, Ariel University
5 shared publications David Schwartz
Division of Epidemiology and Preventive Medicine,1 Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel2
3 shared publicationsAzita Leavitt
Division of Epidemiology and Preventive Medicine,1 Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel2
2 shared publicationsGill Smollan
National Center for Infection Control, Israel Ministry of Health, Tel-Aviv
2 shared publicationsInna Chmelnitsky
National Center for Infection Control, Israel Ministry of Health, Tel-Aviv
2 shared publications
Latest Publications
- Open Access
- 7 October 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (9) , 910-913
High Prevalence of Methicillin-Resistant Staphylococcus aureus Among Residents and Staff of Long-term Care Facilities, Involving Joint and Parallel Evolution
Six long-term care facilities were surveyed for methicillin-resistant Staphylcoccus aureus (MRSA). Among 191 residents, 14% were carriers; 1 strain predominated (ST5-SCCmec II). Among 132 staff members, 11% were positive; 2 strains predominated (ST5-SCCmec II, ST8-SCCmec IV). All strains were Panton-Valentine leukocidin–negative. The epidemiology of MRSA among residents and staff involved joint and parallel evolution.
- 7 October 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (9) , 910-913
Open AccessHigh Prevalence of Methicillin-Resistant Staphylococcus aureus Among Residents and Staff of Long-term Care Facilities, Involving Joint and Parallel Evolution
Six long-term care facilities were surveyed for methicillin-resistant Staphylcoccus aureus (MRSA). Among 191 residents, 14% were carriers; 1 strain predominated (ST5-SCCmec II). Among 132 staff members, 11% were positive; 2 strains predominated (ST5-SCCmec II, ST8-SCCmec IV). All strains were Panton-Valentine leukocidin–negative. The epidemiology of MRSA among residents and staff involved joint and parallel evolution.
- 9 September 2011
- Published by Springer Nature
- p. 105-115
Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)
- 9 September 2011
- Published by Springer Nature
- p. 105-115
Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE)
- Top Cited PapersOpen Access
- 11 February 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (7) , 848-855
Containment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention
Background. During 2006, Israeli hospitals faced a clonal outbreak of carbapenem-resistant Klebsiella pneumoniae that was not controlled by local measures. A nationwide intervention was launched to contain the outbreak and to introduce a strategy to control future dissemination of antibiotic-resistant bacteria in hospitals. Methods. In March 2007, the Ministry of Health issued guidelines mandating physical separation of hospitalized carriers of carbapenem-resistant Enterobacteriaceae (CRE) and dedicated staffing and appointed a professional task force charged with containment. The task force paid site visits at acute-care hospitals, evaluated infection-control policies and laboratory methods, supervised adherence to the guidelines via daily census reports on carriers and their conditions of isolation, provided daily feedback on performance to hospital directors, and intervened additionally when necessary. The initial intervention period was 1 April 2007–31 May 2008. The primary outcome measure was incidence of clinically diagnosed nosocomial CRE cases. Results. By 31 March 2007, 1275 patients were affected in 27 hospitals (175 cases per 1 million population). Prior to the intervention, the monthly incidence of nosocomial CRE was 55.5 cases per 100,000 patient-days. With the intervention, the continuous increase in the incidence of CRE acquisition was halted, and by May 2008, the number of new monthly cases was reduced to 11.7 cases per 100,000 patient-days (P < .001). There was a direct correlation between compliance with isolation guidelines and success in containment of transmission (P = .02). Compliance neutralized the effect of carrier prevalence on new incidence (P = .03). Conclusions. A centrally coordinated intervention succeeded in containing a nationwide CRE outbreak after local measures failed. The intervention demonstrates the importance of strategic planning and national oversight in combating antimicrobial resistance.
- 11 February 2011
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (7) , 848-855
Top Cited PapersOpen AccessContainment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention
Background. During 2006, Israeli hospitals faced a clonal outbreak of carbapenem-resistant Klebsiella pneumoniae that was not controlled by local measures. A nationwide intervention was launched to contain the outbreak and to introduce a strategy to control future dissemination of antibiotic-resistant bacteria in hospitals. Methods. In March 2007, the Ministry of Health issued guidelines mandating physical separation of hospitalized carriers of carbapenem-resistant Enterobacteriaceae (CRE) and dedicated staffing and appointed a professional task force charged with containment. The task force paid site visits at acute-care hospitals, evaluated infection-control policies and laboratory methods, supervised adherence to the guidelines via daily census reports on carriers and their conditions of isolation, provided daily feedback on performance to hospital directors, and intervened additionally when necessary. The initial intervention period was 1 April 2007–31 May 2008. The primary outcome measure was incidence of clinically diagnosed nosocomial CRE cases. Results. By 31 March 2007, 1275 patients were affected in 27 hospitals (175 cases per 1 million population). Prior to the intervention, the monthly incidence of nosocomial CRE was 55.5 cases per 100,000 patient-days. With the intervention, the continuous increase in the incidence of CRE acquisition was halted, and by May 2008, the number of new monthly cases was reduced to 11.7 cases per 100,000 patient-days (P < .001). There was a direct correlation between compliance with isolation guidelines and success in containment of transmission (P = .02). Compliance neutralized the effect of carrier prevalence on new incidence (P = .03). Conclusions. A centrally coordinated intervention succeeded in containing a nationwide CRE outbreak after local measures failed. The intervention demonstrates the importance of strategic planning and national oversight in combating antimicrobial resistance.
- Open Access
- 1 January 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (1) , 106
The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy
The impact of antimicrobial resistance on patient outcomes can be effectively measured only if the appropriateness of the antimicrobial therapy received is properly measured. Definition of appropriate therapy should include not only in vitro susceptibility but also the clinical adequacy of the antibiotic used, taking into account the pathogen isolated, the site of infection, known pharmacokinetic and pharmacodynamic properties of the drug, and dosing. In the absence of these data, the effect of delay or absence of appropriate therapy in patients infected with resistant bacterial pathogens is subject to confounding, and the true effect of resistance on outcomes may be obscured.
- 1 January 2009
- Published by Springer Nature in Critical Care
- Vol. 13 (1) , 106
Open AccessThe effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy
The impact of antimicrobial resistance on patient outcomes can be effectively measured only if the appropriateness of the antimicrobial therapy received is properly measured. Definition of appropriate therapy should include not only in vitro susceptibility but also the clinical adequacy of the antibiotic used, taking into account the pathogen isolated, the site of infection, known pharmacokinetic and pharmacodynamic properties of the drug, and dosing. In the absence of these data, the effect of delay or absence of appropriate therapy in patients infected with resistant bacterial pathogens is subject to confounding, and the true effect of resistance on outcomes may be obscured.
- 24 December 2008
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (24) , 2911-2913
Carbapenem-Resistant Enterobacteriaceae
Opinion from JAMA — Carbapenem-Resistant Enterobacteriaceae — A Potential Threat
- 24 December 2008
- Published by American Medical Association (AMA) in JAMA
- Vol. 300 (24) , 2911-2913
Carbapenem-Resistant Enterobacteriaceae
Opinion from JAMA — Carbapenem-Resistant Enterobacteriaceae — A Potential Threat
- Top Cited Papers
- 1 March 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (3) , 1028-1033
Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.
- 1 March 2008
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (3) , 1028-1033
Top Cited PapersPredictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging nosocomial pathogen. Little is known about its risk factors or mortality. We performed a case-case-control study to assess the risks for CRKP isolation and a retrospective cohort study to assess mortality in three groups of hospitalized adults: (i) patients from whom CRKP was isolated, (ii) patients from whom carbapenem-susceptible Klebsiella spp. (CSKS) were isolated, and (iii) controls from whom no Klebsiella spp. were isolated. After adjustment for length of stay (LOS), the demographics, comorbidities, and exposures of each case group were compared with those of the controls. Significant covariates were incorporated into LOS-adjusted multivariable models. In the mortality study, we evaluated the effect of CRKP on in-hospital death. There were 48 patients with CRKP isolation (21 died [44%]), 56 patients with CSKS isolation (7 died [12.5%]), and 59 controls (1 died [2%]). Independent risk factors for CRKP isolation were poor functional status (odds ratio [OR], 15.4; 95% confidence interval [CI], 4.0 to 58.6; P < 0.001); intensive care unit (ICU) stay (OR, 17.4; 95% CI, 1.5 to 201.9; P = 0.02); and receipt of antibiotics (OR, 4.4; 95% CI, 1.0 to 19.2; P = 0.05), particularly fluoroquinolones (OR, 7.2; 95% CI, 1.1 to 49.4; P = 0.04). CRKP was independently associated with death when patients with CRKP were compared with patients with CSKS (OR, 5.4; 95% CI, 1.7 to 17.1; P = 0.005) and with controls (OR, 6.7; 95% CI, 2.4 to 18.8; P < 0.001). After adjustment for the severity of illness, CRKP isolation remained predictive of death, albeit with a lower OR (for the CRKP group versus the CSKS group, OR, 3.9; 95% CI, 1.1 to 13.6; and P = 0.03; for the CRKP group versus the controls, OR, 5.0; 95% CI, 1.7 to 14.8; and P = 0.004). CRKP affects patients with poor functional status, an ICU stay, and antibiotic exposure and is an independent predictor of death.
- Top Cited Papers
- 17 September 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (5) , 913-920
Mortality and delay in effective therapy associated with extended-spectrum -lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
Objectives We performed a systematic review and meta-analysis to examine the impact of extended-spectrum β-lactamase (ESBL) production on mortality and delay in effective therapy in Enterobacteriaceae bacteraemia.
- 17 September 2007
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 60 (5) , 913-920
Top Cited PapersMortality and delay in effective therapy associated with extended-spectrum -lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
Objectives We performed a systematic review and meta-analysis to examine the impact of extended-spectrum β-lactamase (ESBL) production on mortality and delay in effective therapy in Enterobacteriaceae bacteraemia.
- 14 August 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (11) , 793-800
Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes
We conducted a retrospective matched cohort study to examine the impact of isolation of multi-drug-resistant (MDR) Acinetobacter baumannii on patient outcomes. Cases from whom MDR A. baumannii was isolated in a clinical culture (n = 118) were compared with controls from whom MDR A. baumannii was not isolated (n = 118). Cases and controls were matched according to ward, calendar month of hospitalization, and duration of hospitalization before culture. The following outcomes were compared in multivariable analysis: in-hospital mortality, length of stay, need for mechanical ventilation, and functional status at discharge. MDR A. baumannii was determined to be a pathogen in 72% of cases. In 36% of cases, the patient died, versus 21% of controls (odds ratio [OR] 2.21, 95% confidence interval [CI] 1.17–4.16, P = 0.014). Median length of stay for surviving cases was 17 days, versus 11 for surviving controls (multiplicative effect 1.55, 95% CI 0.99–2.44, P = 0.057). Fifty-two percent of cases required mechanical ventilation, versus 25% of controls (OR 3.72, 95% CI 1.91–7.25, PP = 0.003). In multivariable analysis, clinical isolation of MDR A. baumannii remained a significant predictor of mortality (OR 6.23, 95% CI 1.31–29.5, P = 0.021), need for mechanical ventilation (OR 7.34, 95% CI 2.24–24.0, PP = 0.039). Thus, MDR A. baumannii acquisition is associated with severe adverse outcomes, including increased mortality, need for mechanical ventilation, and reduced functional status.
- 14 August 2007
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (11) , 793-800
Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes
We conducted a retrospective matched cohort study to examine the impact of isolation of multi-drug-resistant (MDR) Acinetobacter baumannii on patient outcomes. Cases from whom MDR A. baumannii was isolated in a clinical culture (n = 118) were compared with controls from whom MDR A. baumannii was not isolated (n = 118). Cases and controls were matched according to ward, calendar month of hospitalization, and duration of hospitalization before culture. The following outcomes were compared in multivariable analysis: in-hospital mortality, length of stay, need for mechanical ventilation, and functional status at discharge. MDR A. baumannii was determined to be a pathogen in 72% of cases. In 36% of cases, the patient died, versus 21% of controls (odds ratio [OR] 2.21, 95% confidence interval [CI] 1.17–4.16, P = 0.014). Median length of stay for surviving cases was 17 days, versus 11 for surviving controls (multiplicative effect 1.55, 95% CI 0.99–2.44, P = 0.057). Fifty-two percent of cases required mechanical ventilation, versus 25% of controls (OR 3.72, 95% CI 1.91–7.25, PP = 0.003). In multivariable analysis, clinical isolation of MDR A. baumannii remained a significant predictor of mortality (OR 6.23, 95% CI 1.31–29.5, P = 0.021), need for mechanical ventilation (OR 7.34, 95% CI 2.24–24.0, PP = 0.039). Thus, MDR A. baumannii acquisition is associated with severe adverse outcomes, including increased mortality, need for mechanical ventilation, and reduced functional status.
- 1 April 2006
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (4) , 1257-1262
Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae
We studied outcomes of extended-spectrum β-lactamase (ESBL) production in Enterobacteriaceae bacteremia. Inpatients with bacteremia caused by ESBL-producing Escherichia coli , Klebsiella spp., or Proteus spp. (cases) were compared with patients with bacteremia caused by non-ESBL producers (controls). Outcomes included mortality, mortality due to infection, length of stay (LOS), delay in appropriate therapy (DAT), discharge to a chronic care facility, and hospital cost. Ninety-nine cases and 99 controls were enrolled. Thirty-five percent of cases died, versus 18% of controls (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3 to 4.7; P = 0.01). Thirty percent of cases died due to infection, versus 16% of controls (OR, 2.3; 95% CI, 1.1 to 4.5; P = 0.03). The median LOS after bacteremia for cases was 11 days (interquartile range, 5 to 21), versus 5 days for controls (interquartile range, 3 to 9) ( P < 0.001). DAT occurred in 66% of cases, versus 7% of controls (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001). Cases were more likely than controls to be discharged to chronic care (52% versus 21%; OR, 4.0; 95% CI, 1.9 to 8.3; P < 0.001). The average hospital cost for cases was 65,509 Israeli shekels, versus 23,538 shekels for controls ( P < 0.001). After adjusting for differences between groups by using multivariable analysis, ESBL production remained a significant predictor of mortality (OR, 3.6; 95% CI, 1.4 to 9.5; P = 0.008), increased LOS (1.56-fold; P = 0.001), DAT (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001), and increased cost (1.57-fold; P = 0.003). The mean increase in equivalent cost attributable to ESBL production was $9,620. ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs.
- 1 April 2006
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (4) , 1257-1262
Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae
We studied outcomes of extended-spectrum β-lactamase (ESBL) production in Enterobacteriaceae bacteremia. Inpatients with bacteremia caused by ESBL-producing Escherichia coli , Klebsiella spp., or Proteus spp. (cases) were compared with patients with bacteremia caused by non-ESBL producers (controls). Outcomes included mortality, mortality due to infection, length of stay (LOS), delay in appropriate therapy (DAT), discharge to a chronic care facility, and hospital cost. Ninety-nine cases and 99 controls were enrolled. Thirty-five percent of cases died, versus 18% of controls (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3 to 4.7; P = 0.01). Thirty percent of cases died due to infection, versus 16% of controls (OR, 2.3; 95% CI, 1.1 to 4.5; P = 0.03). The median LOS after bacteremia for cases was 11 days (interquartile range, 5 to 21), versus 5 days for controls (interquartile range, 3 to 9) ( P < 0.001). DAT occurred in 66% of cases, versus 7% of controls (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001). Cases were more likely than controls to be discharged to chronic care (52% versus 21%; OR, 4.0; 95% CI, 1.9 to 8.3; P < 0.001). The average hospital cost for cases was 65,509 Israeli shekels, versus 23,538 shekels for controls ( P < 0.001). After adjusting for differences between groups by using multivariable analysis, ESBL production remained a significant predictor of mortality (OR, 3.6; 95% CI, 1.4 to 9.5; P = 0.008), increased LOS (1.56-fold; P = 0.001), DAT (OR, 25.1; 95% CI, 10.5 to 60.2; P < 0.001), and increased cost (1.57-fold; P = 0.003). The mean increase in equivalent cost attributable to ESBL production was $9,620. ESBL production was associated with severe adverse outcomes, including higher overall and infection-related mortality, increased LOS, DAT, discharge to chronic care, and higher costs.
- Open Access
- 1 January 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (5) , 164
Antimicrobial resistance and patient outcomes: the hazards of adjustment
Outcomes studies of infections with resistant bacteria often do not account appropriately for intermediate variables – events in the causal pathway between the exposure and the outcome – when controlling for confounders. We discuss how failure to distinguish between confounders and intermediate variables can bias the analysis, and we address methods of approaching this issue.
- 1 January 2006
- Published by Springer Nature in Critical Care
- Vol. 10 (5) , 164
Open AccessAntimicrobial resistance and patient outcomes: the hazards of adjustment
Outcomes studies of infections with resistant bacteria often do not account appropriately for intermediate variables – events in the causal pathway between the exposure and the outcome – when controlling for confounders. We discuss how failure to distinguish between confounders and intermediate variables can bias the analysis, and we address methods of approaching this issue.